amphetamine/dextroamphetamine ER / Generic mfg. - LARVOL DELTA

The Cultural Perception of Abuse in a Multicultural Context and Its Impact on Mental Health: A Case Report. (PubMed, Cureus) - "She was treated with lamotrigine and Adderall XR, with trauma-informed group therapy and psychoeducation about cultural perceptions of abuse. The patient showed improvement in emotional regulation and investment in the treatment; however, she continued to have difficulties with sleep hygiene and alcohol consumption. This case underlines the importance of culturally sensitive psychiatric care and emphasizes that osteopathic practitioners should further work within the framework of the trauma-informed approach with consideration of cultural influence when managing patients, especially those of migrant backgrounds."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Post-traumatic Stress Disorder • Psychiatry

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine (clinicaltrials.gov) - P2 | N=196 | Not yet recruiting | Sponsor: Gagan Joshi

New P2 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Psychiatry

Mixed-Amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in Persons with MS (ACTRIMS Forum 2025) - "This study does not support the use of amphetamines, specifically MAS-XR, as a treatment for CI or IPS in PwMS, which may partly be due to not reaching the required sample size."

Alzheimer's Disease • Cognitive Disorders • Depression • Fatigue • Infectious Disease • Mood Disorders • Multiple Sclerosis • Novel Coronavirus Disease • Psychiatry

Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - P1 | N=30 | Enrolling by invitation | Sponsor: University of California, Los Angeles | Trial completion date: Sep 2025 ➔ Dec 2027 | Trial primary completion date: Sep 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Boston Children's Hospital | Recruiting ➔ Completed | N=30 ➔ 16 | Trial completion date: Aug 2025 ➔ Mar 2024 | Trial primary completion date: Jul 2024 ➔ Mar 2024

Biomarker • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - P2/3 | N=180 | Active, not recruiting | Sponsor: Sarah Morrow | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Mar 2024 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Multiple Sclerosis

Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - P2/3 | N=180 | Recruiting | Sponsor: Sarah Morrow | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Aug 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Multiple Sclerosis

Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - P1 | N=30 | Enrolling by invitation | Sponsor: University of California, Los Angeles | Trial completion date: Jun 2022 ➔ Sep 2025 | Trial primary completion date: Jun 2022 ➔ Sep 2025

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - P4 | N=153 | Completed | Sponsor: University of Cincinnati | Active, not recruiting ➔ Completed | N=240 ➔ 153

Enrollment change • Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Boston Children's Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2023 ➔ Aug 2025 | Trial primary completion date: Jul 2023 ➔ Jul 2024

Biomarker • Enrollment open • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

"These include brand name (= Generic version): - @VYVANSE (Lisdexamfetamine) - Concerta, Ritalin LA, Daytrana, etc (Methylphenidate) - Focalin ER (Dexmethylphenidate ER) @Novartis - Adderall XR - Dexedrine, etc (Dextroamphetamine) - Azstarys These last 12 hours or longer" (@RTorof)

Regional Disparities in Prescription Methamphetamine and Amphetamine Distribution Across the United States. (PubMed, J Atten Disord) - "Overall, prescription amphetamine distribution was common while prescription methamphetamine distribution was rare. The patterns observed in distribution are likely the result of stigmatization, differences in accessibility, and the efforts of initiatives such as the Montana Meth Project."

Journal

BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Boston Children's Hospital

Biomarker • New P1 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Therapeutic Interchange Cost-savings Initiative: Lisdexamfetamine to Amphetamine/dextroamphetamine ER (ASHP 2022) - No abstract available

HEOR

Following Pediatric Bipolar Symptoms Through Developmental Transitions: New Findings and Directions (AACAP 2022) - "Methods Melissa DelBello, MD, will present comparisons of clinical and neural characteristics in youth who have ADHD with and without a parent with BD and healthy-comparison youth, and among youth who have ADHD with and without a parent with BD following 12 weeks of treatment with Adderall XR (dextroamphetamine/amphetamine)...Vogel-Hammen and Luby find that PBD showed continuity into adulthood and that alterations in sleep and circadian rhythm were found in adults who had BD as children. Conclusions Manpreet Singh, MD will serve as discussant and will synthesize the studies presented and challenge speakers to translate their findings into real-world application to maximize clinical utility and patient education."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Pediatrics • Psychiatry

Posterior Reversible Encephalopathy Syndrome With Visual Disturbances in an Adolescent After Overdose With Adderall XR: A Case Report. (PubMed, J Neuroophthalmol) - No abstract available

Journal • CNS Disorders

"Is it me…or is #adderall not working like it used to🤷🏼‍♀️💊 #ADHD #ADD #FOCUS @TevaUSA #diditchange #notworking #adderallxr #AskingForAFriend" (@cure4emmaT1D)

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

"@TakedaPharma I'm trying to determine if both @Amgen and @PrascoAGs produce authorized generics of Adderall XR. Pharmacy unable to order Prasco from supplier, is Amgen an option?" (@EusticeTheSheep)

Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - P2/3 | N=180 | Recruiting | Sponsor: Sarah Morrow | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Multiple Sclerosis

NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - P4 | N=240 | Active, not recruiting | Sponsor: University of Cincinnati | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2021 ➔ Apr 2022

Enrollment closed • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - P1; N=30; Enrolling by invitation; Sponsor: University of California, Los Angeles; Not yet recruiting ➔ Enrolling by invitation

Clinical • Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - P4; N=240; Recruiting; Sponsor: University of Cincinnati; Trial completion date: Aug 2020 ➔ Dec 2022; Trial primary completion date: Aug 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • MRI

Comparative Bioavailability of Amphetamine Extended-Release Oral Suspension and Extended-Release Mixed Amphetamine Salts. (PubMed, CNS Spectr) - "The bioavailability of a single 7.5 mL dose of AMPH EROS 2.5 mg/mL was comparable to a single 30 mg capsule dose of ER MAS. AMPH EROS (both d- and l-amphetamine) showed equivalent peak and overall exposure to ER MAS under fasted conditions."

Journal

A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - P1/2; N=145; Completed; Sponsor: New York State Psychiatric Institute; Active, not recruiting ➔ Completed; Trial completion date: May 2022 ➔ Jan 2021; Trial primary completion date: May 2021 ➔ Jan 2021

Trial completion • Trial completion date • Trial primary completion date

Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - P2/3; N=180; Recruiting; Sponsor: Sarah Morrow; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Aug 2020 ➔ Aug 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Multiple Sclerosis